ย 
  • MJ

โš•๏ธ $BNGO (BioNano Genomics Inc) ๐™ž๐™จ ๐™—๐™–๐™˜๐™  ๐™ค๐™ฃ ๐™„๐™ฃ๐™ซ๐™š๐™จ๐™ฉ๐™ค๐™ง๐™จ ๐™๐™–๐™™๐™–๐™ง ๐Ÿ“ˆ

๐˜ฝ๐˜ผ๐˜พ๐™†๐™๐™‚๐™๐™Š๐™๐™‰๐˜ฟ

Bionano Genomics, Inc. is a life sciences instrumentation company in the genome analysis space. The Company develops and markets the Saphyr system. The Companyโ€™s products include Sequencing for Discovery Research and Cytogenetics.


Cytogenetics provide a clinical diagnosis, cytogenetic tests detect known variations that are linked to specific diseases or therapeutic responses. Saphyr system is platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics.


Sequencing for Discovery Research is primarily used to find single nucleotide variations responsible for disease or therapeutic response. The Companyโ€™s subsidiary, Lineagen, Inc., provides molecular diagnostics services for individuals. (Source: Refinitiv)


๐™๐™๐™‰๐˜ฟ๐˜ผ๐™ˆ๐™€๐™‰๐™๐˜ผ๐™‡๐™Ž

BNGO, together with $ASXC (Asensus Surgical Inc.) , were two of my amazing choices at the end of 2020. BNGO, although it almost halved, is still 831% up for me. Despite that, the company has still a big potential, so let us look into the fundamentals:


๐Ÿ”น๏ธ Market Cap of $2.34B

๐Ÿ”น๏ธ Revenue of 16.4M in FY1 and 57.3M in FY3

๐Ÿ”น๏ธ Revenue growth of over 90%!

๐Ÿ”น๏ธ Short Interest at 13.1%

๐Ÿ”น๏ธ Debt to Capital at 3.94%

๐Ÿ”น๏ธ Cash of 362M

๐Ÿ”น๏ธ Upside Potential 43%


In terms of Segments, 37% of Revenue is attributed to Consumables, 36% to Instruments and 27% to Services and Other. North America brings 53% of Revenue, 37% is generated in EMEA and 10% in Asia Pacific.


The biggest Institutional Investors are Renaissance Technologies and The Vanguard Group at 3.4% and 3.33% respectively. Invesco has 1.5% while Blackrock 1.2%


๐™๐™€๐˜พ๐™€๐™‰๐™ ๐˜ฟ๐™€๐™‘๐™€๐™‡๐™Š๐™‹๐™ˆ๐™€๐™‰๐™๐™Ž

๐Ÿ”น๏ธ On 07.06.2021, BNGO appointed Jason Priar as its Chief Commercial Officer.

๐Ÿ”น๏ธ Cutter & CO Brokerage Inc. took a new position in BNGO on 06.06.2021

๐Ÿ”น๏ธ There has been a speculation about WSB and short squeeze on BNGO recently

๐Ÿ”น๏ธ CFO acquired shares - news reported on 28.05.2021

๐Ÿ”น๏ธ News from 26.05 on Seeking Alpha talks about the CEO - Robert Holmlin - presenting at Oppenheimer MedTech, Tools & Diagnostic Summit


๐˜พ๐™Š๐™‰๐˜พ๐™‡๐™๐™Ž๐™„๐™Š๐™‰

BNGO went from below 1 USD to almost 16 USD in relatively short time and then it went as low as 4. Trading at 8.4 gives up an Upside Potential of 43% and, if the rumours were to be believed, it may be a target of speculation in the coming days/weeks. BNGO will also be included in Russell 3000 which should help the stock price, not only to grow but to also find a solid support level. For me, it is a long term hold as I took my profits as high as 15.39.


bionanogenomics.com/


PS. All my investments and portfolio are public. To join eToro please follow the link: https://bit.ly/3i7Yo3C


Please note that CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.

19 views0 comments
ย